2000.1000 -4.30 (-0.21%)
NSE Sep 04, 2025 12:19 PM
Volume: 287.3K
 

Motilal Oswal
Glenmark Pharma (GNP) reported revenues of INR18.8b (+16% YoY; 2% miss), driven by strong growth in the US, Europe, ROW and API businesses. EBITDA margin came in at 17%, in line with our estimate. Reported PAT of INR2.3b (+24% YoY) was 44% above...
Glenmark Pharmaceuticals Ltd. has gained 32.11% in the last 3 Months
More from Glenmark Pharmaceuticals Ltd.
Recommended